We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-of-Its-Kind AI-Enabled Service Digitizes Glass Slides to Help Labs Create Digital Pathology Repositories

By LabMedica International staff writers
Posted on 25 Mar 2022

Despite the potential value and impact of digitizing pathology archives, few pathology labs have achieved large scale digital libraries. More...

Due to the vastly different slide preparation methods over the years as well as the deterioration of slides in storage, the highly labor-intensive process often results in poor quality and inconsistent images. Now, a vertically integrated solution offers a completely automated means for digitization at scale, enabling significant operational efficiencies by limiting human intervention.

Pramana, Inc. (Cambridge, MA, USA) has launched its Digital Pathology as a Service (DPaaS) solution for creating digital pathology repositories. The DPaaS platform offers a first-of-its-kind service to efficiently digitize pathology slides to meet the needs of pathologists, researchers, and clinicians. Pramana uses its intelligent whole slide image acquisition system, fed by a robot and analyzed by proprietary algorithms, to achieve 100% real-time, fully automated quality assessment. A single scanning cluster is capable of scanning over 1,000 slides per day, and Pramana can scale up or down efficiently to achieve customer-desired throughput. Pramana has announced its first commercial agreement with Mayo Clinic, a multi-year collaboration that includes an industry-leading initiative to digitize five million slides – one of the largest digitization efforts in the world to date, at an unprecedented rate.

“It is often misconstrued that the challenges with going digital for tissue and body fluid slides end with the purchase of a scanner,” said Prasanth Perugupalli, Chief Product Officer at Pramana. “We realized that the greater pain and costs lie in the human capital needed to operate the scanners, which includes making the correct parametric selections and qualifying each whole slide image for any errors after the scanning is completed. Pramana’s DPaaS solution overcomes these challenges with minimal burden on the labs and delivers quality-assured whole slide images with standardized and open data formats.”

Related Links:
Pramana, Inc. 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Clinical Informatics Platform
CLARION™
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.